THE BOTTOM LINE
Since October 30, 2026, HHS says it won't take enforcement action against licensed 503A pharmacies and physicians that compound MOTS-c acetate for subcutaneous or intramuscular injection under its conditions. Oral, topical and nasal MOTS-c are not covered. MOTS-c is not FDA approved, it passed the July advisory vote 7 to 5 with two abstentions, and the evidence for benefit in people is mostly early-stage.
SIDE-BY-SIDE
What actually differs
What changed on October 28
MOTS-c is one of six peptides in HHS's October 28, 2026 enforcement discretion policy. Starting October 30, HHS says it does not intend to act against covered compounders that make MOTS-c acetate for injection under the policy's conditions.
On July 23, 2026, FDA's advisory committee recommended MOTS-c for the 503A Bulks List 7 to 5 with two abstentions, the tightest margin of the six. It was nominated for obesity and osteoporosis.
The policy's other conditions apply to every one of the six peptides: the ingredient must come from an FDA-registered facility with a valid certificate of analysis made under CGMP, the product may contain only one active ingredient, the only delivery device allowed is an FDA 510(k)-cleared syringe, the label must say it is a compounded drug not for resale, and serious adverse events must be reported to FDA MedWatch.
What it didn't change
It did not approve the peptide; compounded drugs are not FDA approved. It did not add it to the 503A Bulks List, which still requires formal rulemaking. It does not cover "research use only" vials, blends with other peptides, or any route the policy doesn't list. HHS calls the policy interim and says it can revisit it; public comments are open through November 13, 2026.
What MOTS-c is, and what the evidence says
MOTS-c is a short peptide encoded in mitochondrial DNA. It's marketed as an "exercise mimetic" because animal and cell studies link it to metabolism, insulin sensitivity and responses to exercise.
Those findings are mostly from animals and lab work. FDA's reviewers did not find human safety studies for MOTS-c itself. Weight-loss or performance claims in people are not established, and for weight loss specifically, FDA-approved GLP-1 medications have far more human evidence.
Who should slow down
Anyone with diabetes or on glucose-lowering medication, since MOTS-c is studied for effects on metabolism. Anyone pregnant or breastfeeding. Athletes in tested sport should check the WADA list; unapproved peptides generally fall under its S0 category.
Ask any provider: Is a licensed clinician reviewing my case? Which state-licensed 503A pharmacy fills it? Is there a certificate of analysis for the ingredient? Is it this peptide alone, with no blend? Is the route one the policy covers? What's the full price, including refills, and how do I cancel? If anything says "FDA approved," treat that as a red flag.
QUICK ANSWERS
Is MOTS-c legal now?
Since October 30, 2026, licensed 503A pharmacies and physicians can compound MOTS-c acetate for subcutaneous or intramuscular injection without federal enforcement, if they meet the HHS policy conditions. It is not FDA approved.
Is oral MOTS-c covered?
No. The policy covers injectable MOTS-c only.
PRIMARY & AUTHORITATIVE SOURCES
Check the underlying record
Regulatory status and labeling can change. Sources were reviewed on the article update date; current prescribing information controls.COMPARE THE CARE MODEL
Medication is only one part of the decision.
Use the 30-second filter to identify the costs, clinical safeguards and service terms worth checking before you enroll.
Find my starting point →